Key Takeaways
- Grifols is the sole major commercial plasma collector in Canada, operating 17 sites in six provinces and holding licences granted by Canadian Blood Services.
- In October 2025, University of Winnipeg student Rodiyat Alabede died while donating plasma at a Winnipeg Grifols clinic; an autopsy indicated her heart rhythm deteriorated and stopped during the procedure.
- A second, undisclosed donor death occurred at a different Winnipeg Grifols centre in January 2025.
- Health Canada inspections after the deaths found multiple deficiencies, notably staff inadequately trained to respond to alarms on donation machines.
- On April 1, Health Canada imposed conditions on 16 of Grifols’s licences, including limits on simultaneous donor numbers, and announced plans to inspect three Ontario sites.
- Although Health Canada declared on April 3 that its review found “no linkage” between the deaths and the donation process, Alabede’s family disputes this conclusion, citing discrepancies in government reports and the donor’s pre‑existing heart condition.
- Federal Health Minister Marjorie Michel acknowledged problems with Grifols and said the matter remains under investigation, but she declined to testify before a parliamentary health committee, prompting criticism from opposition MPs.
- Concerns persist about the secrecy of the agreement between Canadian Blood Services and Grifols, including the potential for plasma‑derived medicines made in Canada to be sold abroad without transparent oversight.
Background on Grifols’ Role in Canada
Grifols, a Barcelona‑based pharmaceutical corporation, is the only major for‑profit collector of source plasma in Canada. It operates 17 donation centres across six provinces and holds licences to collect plasma that are granted by Canadian Blood Services, the national authority overseeing blood and plasma safety. The company’s presence has grown steadily as demand for plasma‑derived therapies—such as immunoglobulins and clotting factors—has increased worldwide. Because Grifols is the dominant private player, its practices are subject to heightened scrutiny from federal regulators, provincial health ministries, and advocacy groups concerned about donor safety and the ethics of commodifying a vital biological resource.
The October 2025 Death of Rodiyat Alabede
On October 25, 2025, Rodiyat Alabede, a 22‑year‑old University of Winnipeg student, collapsed while donating plasma at a Winnipeg clinic owned by Grifols. According to the autopsy report released by provincial authorities, her heart rhythm began to deteriorate during the donation and subsequently ceased, leading to cardiac arrest. Alabede’s family has asserted that she suffered from an undisclosed heart condition that would have placed her at elevated risk for a cardiac event during the physically demanding donation process. They contend that the clinic’s staff failed to recognize or respond appropriately to early warning signs, a claim that has become central to the ongoing controversy surrounding her death.
A Second, Undisclosed Donor Death
In January 2025, another donor died at a different Winnipeg Grifols collection site. The circumstances of that death have not been made public, and Health Canada has not released detailed findings. Nevertheless, the occurrence of a second fatality within a short time frame prompted regulators to scrutinize Grifols’ operational protocols more closely. The lack of transparency around this incident has fueled criticism from opposition politicians and public‑health advocates, who argue that the public deserves full disclosure when donor safety is potentially compromised.
Health Canada’s Inspection Findings
Following both deaths, Health Canada dispatched inspectors to the affected Winnipeg clinics. Internal inspection reports obtained by The Globe and Mail revealed several deficiencies, the most significant being that staff members were not adequately trained to handle alarms triggered by the donation machines. These alarms are designed to alert operators to adverse physiological changes in donors, such as hypotension or arrhythmia. The reports also noted inconsistencies in emergency response procedures and gaps in documentation of donor vitals during the donation process. These findings suggested systemic shortcomings that could have contributed to the failure to intervene in a timely manner during Alabede’s event.
Regulatory Actions and Licence Conditions
In response to the inspection outcomes, Health Canada announced on April 1, 2025, that it would impose conditions on 16 of Grifols’s licences across Canada. The conditions include limiting the number of donors that may be attended to simultaneously at each site, mandating additional staff training on machine alarms and emergency protocols, and requiring more rigorous monitoring of donor vital signs. Health Canada also stated that it would conduct targeted inspections of three Grifols plasma collection centres in Ontario to verify compliance with the new requirements. These measures reflect a precautionary approach aimed at mitigating immediate risks while a broader review continues.
Health Canada’s Statement on Causality
On April 3, 2025, Health Canada issued a public statement asserting that its assessment of the two donor deaths had been completed and that “no linkage” had been established between the deaths and the plasma donation process itself. The agency emphasized that, based on the evidence reviewed, there was insufficient proof to conclude that the donation procedure directly caused the fatalities. This conclusion has been vigorously contested by Alabede’s family, who argue that the government’s reports contain inconsistencies and that the presence of a pre‑existing cardiac condition in the donor makes a causal link plausible. The family’s spokesperson, Kat Lanteigne, has called for a re‑examination of the data and for greater transparency from both Health Canada and Grifols.
Ministerial Response and Parliamentary Pressure
Federal Health Minister Marjorie Michel addressed the issue during a appearance before the House of Commons finance committee on May 28, 2025. Speaking in French, she acknowledged that there were “problems with Grifols” and described the deaths as “very sad.” She began to comment on the lack of a direct link between Grifols and “something else,” but did not finish the sentence, later stating that the matter remains under investigation and that the federal government is collaborating with provincial authorities, which have a role in overseeing the Grifols‑Canadian Blood Services agreement. When asked whether her remarks signaled a reopened review, her spokesperson indicated that the government is continuing to follow up on the families’ concerns and is examining gaps identified by the families’ representatives to strengthen donor and recipient protections.
Opposition Criticism and Calls for Testimony
Opposition members, notably Conservative MP Dan Mazier and Bloc Québécois representatives, have pressed for Minister Michel to testify before the health committee to answer questions about the Grifols‑Canadian Blood Services contract, which has never been made public. Mazier criticized the minister for not having read the agreement and for refusing to appear before the committee, asserting that this demonstrates a lack of seriousness in addressing regulatory oversights. The Liberals on the health committee have blocked attempts to compel her testimony, citing her prior five appearances on various topics and scheduling constraints. The opposition argues that the secrecy surrounding the agreement impedes parliamentary accountability and raises concerns about whether plasma collected in Canada could be used to manufacture pharmaceutical products sold abroad without adequate oversight.
Ethical and Economic Implications of Plasma as a “Liquid Asset”
The increasing commercialization of source plasma has led commentators to describe it as a “liquid asset,” highlighting its value in the global market for life‑saving therapies. This framing raises ethical questions about compensating donors, the potential for exploitation of vulnerable populations, and the balance between ensuring a sufficient supply of plasma‑derived medicines and protecting donor safety. Advocates warn that treating plasma primarily as a commodity may incentivize practices that prioritize throughput over rigorous donor monitoring, a concern underscored by the training deficiencies identified in the Grifols clinics. Ongoing debates centre on whether stronger federal oversight, greater transparency in contracts, and possibly a shift toward non‑remunerated, volunteer‑based donation models could better safeguard both donors and recipients while meeting clinical demand.
Conclusion
The case of Rodiyat Alabede’s death, coupled with a second undisclosed fatality and the regulatory shortcomings uncovered at Grifols facilities, has ignited a multifaceted controversy involving donor safety, governmental oversight, corporate accountability, and the ethics of plasma commodification. While Health Canada has maintained that no direct causal link has been proven, the family’s dispute, the identified procedural gaps, and the political pressure for greater transparency indicate that the issue remains unresolved. Moving forward, clarifying the terms of the Canadian Blood Services‑Grifols agreement, enforcing rigorous staff training, and ensuring open communication with donor families will be essential to restore public confidence in Canada’s plasma collection system.